January 11, 2019

CDMO Outsourcing Trends

Outsourcing to Contract Development and Manufacturing Organizations (CDMOs) has been on the rise, driven by increasingly complex drug candidates and the expertise they require, and now, increasingly for regulatory affairs.   Protein forms of an antibody ...

Continue Reading

January 7, 2019

In Vivo Glycan Engineering Via the Mannosidase I Inhibitor (Kifunenesine) Improves Efficacy of Rituximab Manufacture in Nicotiana benthamiana Plants

Monoclonal antibodies (mAbs) represent the fastest growing class of therapeutics [1,2] and have been especially beneficial in the treatment of cancer [3]. Since the approval of the first anti-cancer monoclonal antibody in 1986 [4], several innovations ...

Continue Reading

September 10, 2018

Plant Derived Rituximab? iBio Inks "Green" Bioreactor Tech Deal in China

According to the agreement, Delaware, US-based iBio will provide process development and manufacturing services at its Texas facility, and will assist CC-Pharming in preparing a site for eventual manufacturing in China. The first project will focus on ...

Continue Reading

June 11, 2018

Plant-Made E2 Glycoprotein Single-Dose Vaccine Protects Pigs against Classical Swine Fever

Introduction Classical Swine Fever (CSF) is a highly contagious hemorrhagic disease affecting pigs. CSF outbreaks have caused substantial economic damages to the swine industry worldwide, including a major outbreak in the Netherlands between 1997 and ...

Continue Reading

January 31, 2018

Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies

Introduction Therapeutic glycoproteins represent a predominant disease treatment category among biopharmaceuticals approved or in clinical development. N-linked glycosylation is a very important post-translational modification that can profoundly affect ...

Continue Reading
1 2 3 4 5